Skip to main content
Premium Trial:

Request an Annual Quote

Nabsys Raises $7M in Series B Funding to Boost Development of Nanopore Sequencing Platform

Premium

This story was originally published on February 17, 2010.

Nabsys has raised $7 million from a Series B equity financing round, the company said today.

The Providence, RI-based company will use the funding to accelerate the development and commercialization of its nanopore-based DNA sequencing platform.

The startup company, which resulted from the merger of two Brown University spinouts in late 2006 (see In Sequence 1/9/2007), is working on a sequencing platform that combines sequencing-by-hybridization with solid-state electrically-addressable nanopore arrays.

Stata Venture Partners led the Series B round, in which existing investor Point Judith Capital participated as well. The funding follows almost a year after Nabsys closed a $4 million Series A equity round (see In Sequence 5/5/2009).

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.